Therapy News and Research

RSS

Wings for Life World Run to fund breakthrough clinical study on spinal cord injury

It all started with a single toe. Even today, Dr. Susan Harkema recalls the words spoken by one of the research participants: "Look Susie, I can move my toe." The patient's name was Rob Summers and he was completely paralyzed from the neck down. After a car accident he was told he would never be able to walk again.

6 Mar 2015

Non-viral gene therapy provides relief for diabetics with constant foot pain

Walking barefoot on sand "felt like walking on glass" for Keith Wenckowski, who has lived with type-one diabetes for more than two decades.

6 Mar 2015

Magnetic material may open doors to new strategy for hyperthermia cancer treatment

An extraordinary self-regulating heating effect that can be achieved in a particular type of magnetic material may open the doors to a new strategy for hyperthermia cancer treatment.

5 Mar 2015

Good news for patients suffering from shingles

The Journal of Drugs in Dermatology is delighted to present new findings from the Mayo Clinic's Department of Dermatology showing possible relief from the complications and pain secondary to Herpes Zoster, commonly known as shingles.

5 Mar 2015

LUNGevity applauds FDA's approval of Opdivo drug

LUNGevity Foundation, the nation's leading lung cancer nonprofit, applauds the Food and Drug Administration's approval of Bristol Myers Squibb's new immunotherapy drug Opdivo (nivolumab). Opdivo and other immunotherapy treatments add another critical new treatment option to fight lung cancer by harnessing the power of a patient's own immune system to fight cancerous cells.

5 Mar 2015

Mallinckrodt enters into definitive agreement to acquire Ikaria

Mallinckrodt plc, a leading global specialty biopharmaceutical company, and Ikaria, Inc. a privately-held critical care company, announced today that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will acquire Ikaria, Inc. from a Madison Dearborn-led investor group in a transaction valued at approximately $2.3 billion.

5 Mar 2015

Pediatric Cancer Genome Project identifies genetic basis of three pediatric melanoma subtypes

The St. Jude Children's Research Hospital—Washington University Pediatric Cancer Genome Project found that melanoma in some adolescent and adult patients involves many of the same genetic alterations and would likely respond to the same therapy.

5 Mar 2015

Valley Hospital becomes first hospital in New Jersey to use minimally-invasive approach to treat PAD

The Valley Hospital today announced it was the first hospital in New Jersey to use a recently approved device to offer a minimally-invasive approach to the treatment of peripheral artery disease (PAD) in the upper leg, a serious and common condition associated with an increased risk for heart attack and stroke.

5 Mar 2015

Study: Omega-3 fatty acids appear to protect heart function among heart attack survivors

Taking omega-3 fatty acids appeared to lower inflammation and guard against further declines in heart function among recent heart attack survivors already receiving optimal standard care, according to results from a randomized, controlled trial to be presented at the American College of Cardiology's 64th Annual Scientific Session in San Diego.

5 Mar 2015

ILROG guideline outlines treatment options for pediatric Hodgkin lymphoma patients

The International Lymphoma Radiation Oncology Group has issued a guideline that outlines the use of 3-D computed tomography (CT)-based radiation therapy planning and volumetric image guidance to more effectively treat pediatric Hodgkin lymphoma and to reduce the radiation dose to normal tissue, thus decreasing the risk of late side effects.

4 Mar 2015

Symbiomix Therapeutics announces positive results from SYM-1219 Phase 1 clinical program

Symbiomix Therapeutics, a late-stage, privately held biopharmaceutical company developing innovative medicines for serious women's health infections, today announced results from its Phase 1 clinical program demonstrating that its lead product candidate, SYM-1219, was safe and well tolerated and had predictable pharmacokinetics (PK), and that contraceptive efficacy for birth control pills would not be altered by SYM-1219 administration.

4 Mar 2015

Restore Health Rehabilitation opens modern medical resort in Southern Maryland

Southern Maryland's first modern medical resort officially opened its doors with a ribbon-cutting ceremony on February 27.

4 Mar 2015

PINN partners with Clinicient to strengthen clinical and business decisions

Clinicient Inc., a leader in outpatient rehabilitation business solutions, announced today that People's Injury Network Northwest, a preeminent industrial rehabilitation physical and occupational therapy provider in Washington state, has selected Clinicient's PracticeInsight cloud-based EMR and billing solutions.

4 Mar 2015

Diplomat Pharmacy selected to distribute Novartis' COSENTYX (secukinumab)

Diplomat Pharmacy, Inc. has been selected to the Novartis limited-distribution panel to distribute COSENTYX (secukinumab), a drug approved in January by the U.S. Food and Drug Administration to treat adults with moderate-to-severe plaque psoriasis.

4 Mar 2015

Enrollment completed in Pharma Two B's P2B001 Phase IIb study for Parkinson's disease treatment

Pharma Two B announced today that enrollment has been completed in the company's Phase IIb study of P2B001 for the treatment of early stage Parkinson's disease. One hundred and forty-nine patients enrolled in the study conducted at 29 clinical sites throughout the US and Israel.

4 Mar 2015

$New guidance to prevent bisphosphonate-related atypical femoral fractures$

New guidance to prevent bisphosphonate-related atypical femoral fractures

Physicians worldwide frequently prescribe bisphosphonates such as alendronate (Fosamax) and ibandronate (Boniva) to treat osteoporosis and prevent fragility fractures. Unfortunately, long-term bisphosphonate use has been linked to an increased risk of atypical femoral fractures.

4 Mar 2015

Novogen's TRXE-009 therapy shows promise against brain cancer

Australian/US biotechnology company, Novogen Limited, today announces that it has confirmed that one of its lead candidate products, TRXE-009, is showing the potential to become an important new therapy in the fight against adult and pediatric brain cancer.

4 Mar 2015

SARAH study completes patient enrolment to evaluate treatment for primary liver cancer

SARAH, a large French study of patients with advanced, inoperable primary liver cancer (hepatocellular carcinoma, or HCC) has completed patient enrolment, exceeding its 400-patient target, according to its principal investigator, Professor Valérie Vilgrain MD, PhD, Department of Radiology, Beaujon Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP) and Université Paris Diderot, Sorbonne Paris Cité, France.

4 Mar 2015

New study shows who benefits most from statin therapy

Research has demonstrated that the risk for developing coronary heart disease depends on a host of risk factors that are related both to lifestyle and genetics. In a new study from Brigham and Women's Hospital, Washington University School of Medicine in St. Louis, and Massachusetts General Hospital, researchers tested whether a composite of genetic variants could identify the risk of cardiovascular death and heart attacks as well as identify individuals who derived greater clinical benefit from statin therapy.

4 Mar 2015

Novel drug mechanism shows promise against glioma cells

Researchers at UC Davis have developed and characterized a molecule that interferes with the internal regulation of cancer cells, causing them to self-destruct. This novel mechanism was found to be effective against glioma cells - responsible for a usually fatal type of brain cancer - and could be applicable to other highly aggressive cancers.

4 Mar 2015

Therapy News and Research

Wings for Life World Run to fund breakthrough clinical study on spinal cord injury

Non-viral gene therapy provides relief for diabetics with constant foot pain

Magnetic material may open doors to new strategy for hyperthermia cancer treatment

Good news for patients suffering from shingles

LUNGevity applauds FDA's approval of Opdivo drug

Mallinckrodt enters into definitive agreement to acquire Ikaria

Pediatric Cancer Genome Project identifies genetic basis of three pediatric melanoma subtypes

Valley Hospital becomes first hospital in New Jersey to use minimally-invasive approach to treat PAD

Study: Omega-3 fatty acids appear to protect heart function among heart attack survivors

ILROG guideline outlines treatment options for pediatric Hodgkin lymphoma patients

Symbiomix Therapeutics announces positive results from SYM-1219 Phase 1 clinical program

Restore Health Rehabilitation opens modern medical resort in Southern Maryland

PINN partners with Clinicient to strengthen clinical and business decisions

Diplomat Pharmacy selected to distribute Novartis' COSENTYX (secukinumab)

Enrollment completed in Pharma Two B's P2B001 Phase IIb study for Parkinson's disease treatment

New guidance to prevent bisphosphonate-related atypical femoral fractures

Novogen's TRXE-009 therapy shows promise against brain cancer

SARAH study completes patient enrolment to evaluate treatment for primary liver cancer

New study shows who benefits most from statin therapy

Novel drug mechanism shows promise against glioma cells

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News